CLINICAL TRIALS PROFILE FOR ZOLINZA
✉ Email this page to a colleague
All Clinical Trials for Zolinza
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00121225 ↗ | Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma | Completed | National Cancer Institute (NCI) | Phase 2 | 2005-09-01 | This phase II trial is studying how well vorinostat works in treating patients with metastatic or unresectable melanoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. |
| NCT00127101 ↗ | An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED) | Terminated | Merck Sharp & Dohme Corp. | Phase 1 | 2005-09-01 | This is an investigational study that increases the dosage to determine the safety/tolerability, and efficacy of a histone deacetylase inhibitor in combination with Targretin in patients with cutaneous T-cell lymphoma in patients who have failed at least one prior systemic therapy. |
| NCT00128102 ↗ | Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2005-06-30 | The goal of this study is to assess the efficacy and safety of an oral investigational drug suberoylanilide hydroxamic acid (vorinostat, MK-0683) compared to placebo, in the treatment of participants with advanced malignant pleural mesothelioma who have failed at least one prior chemotherapy regimen. The primary hypotheses are the following: (1) vorinostat improves overall survival (OS) compared to placebo (2) vorinostat is generally safe and well tolerated. |
| NCT00132002 ↗ | Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer | Terminated | National Cancer Institute (NCI) | Phase 2 | 2005-06-01 | This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with progressive stage IV breast cancer. Drugs used in chemotherapy, such as suberoylanilide hydroxamic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Suberoylanilide hydroxamic acid may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth |
| NCT00132028 ↗ | Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma | Completed | National Cancer Institute (NCI) | Phase 2 | 2005-09-01 | This phase II trial is studying how well vorinostat works in treating patients with relapsed or refractory advanced Hodgkin's lymphoma. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Zolinza
Condition Name
| Condition Name for Zolinza | |
| Intervention | Trials |
| Lymphoma | 11 |
| Unspecified Adult Solid Tumor, Protocol Specific | 10 |
| Recurrent Adult Acute Myeloid Leukemia | 10 |
| Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | 8 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for Zolinza
Trials by Country
Clinical Trial Progress for Zolinza
Clinical Trial Phase
Clinical Trial Sponsors for Zolinza
Sponsor Name
